JP2024505151A5 - - Google Patents

Info

Publication number
JP2024505151A5
JP2024505151A5 JP2023541965A JP2023541965A JP2024505151A5 JP 2024505151 A5 JP2024505151 A5 JP 2024505151A5 JP 2023541965 A JP2023541965 A JP 2023541965A JP 2023541965 A JP2023541965 A JP 2023541965A JP 2024505151 A5 JP2024505151 A5 JP 2024505151A5
Authority
JP
Japan
Prior art keywords
lnp
oligonucleotide
sna
toll
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505151A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/012023 external-priority patent/WO2022155149A1/en
Publication of JP2024505151A publication Critical patent/JP2024505151A/ja
Publication of JP2024505151A5 publication Critical patent/JP2024505151A5/ja
Pending legal-status Critical Current

Links

JP2023541965A 2021-01-12 2022-01-11 脂質ナノ粒子球状核酸 Pending JP2024505151A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163136501P 2021-01-12 2021-01-12
US63/136,501 2021-01-12
PCT/US2022/012023 WO2022155149A1 (en) 2021-01-12 2022-01-11 Lipid nanoparticle spherical nucleic acids

Publications (2)

Publication Number Publication Date
JP2024505151A JP2024505151A (ja) 2024-02-05
JP2024505151A5 true JP2024505151A5 (cg-RX-API-DMAC7.html) 2025-01-21

Family

ID=82447506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541965A Pending JP2024505151A (ja) 2021-01-12 2022-01-11 脂質ナノ粒子球状核酸

Country Status (5)

Country Link
US (1) US20240309367A1 (cg-RX-API-DMAC7.html)
EP (1) EP4277590A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024505151A (cg-RX-API-DMAC7.html)
CN (1) CN116940324A (cg-RX-API-DMAC7.html)
WO (1) WO2022155149A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12702719B2 (en) 2019-03-06 2026-08-11 Northwestern University Hairpin-like oligonucleotide-conjugated spherical nucleic acid
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
EP4304640A1 (en) 2021-03-12 2024-01-17 Northwestern University Antiviral vaccines using spherical nucleic acids
WO2024091579A2 (en) * 2022-10-27 2024-05-02 Seawolf Therapeutics, Inc. Nucleic acid payload delivery systems, compositions, and methods
EP4630061A1 (en) * 2022-12-08 2025-10-15 Nanovation Therapeutics Inc. Lipid nanoparticles comprising elevated neutral lipid and a targeting moiety for targeted delivery of nucleic acid
WO2026006618A1 (en) * 2024-06-26 2026-01-02 Northwestern University Lipid nanoparticle spherical nucleic acids for genome engineering

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
IT1397011B1 (it) * 2009-10-14 2012-12-20 Univ Ferrara Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.
EP2860255A1 (en) * 2013-10-14 2015-04-15 Technische Universität Graz Compositions comprising cationic and neutral lipids for transfecting nucleic acid molecules into eukaryotic cells
WO2015089419A2 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
US20180214376A1 (en) * 2015-07-14 2018-08-02 Exicure, Inc. Spherical nucleic acid (sna)-mediated delivery of lipid-complexes to cells
WO2018067302A2 (en) * 2016-09-19 2018-04-12 North Western University Therapeutic effects of cellular delivery of small molecules and macromolecules with liposomal spherical nucleic acids
EP3538067A1 (en) * 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US20200248183A1 (en) * 2017-04-03 2020-08-06 Subbarao Nallagatla Tlr9-targeted spherical nucleic acids having potent antitumor activity
MA49421A (fr) * 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
JP2020526558A (ja) * 2017-07-13 2020-08-31 ノースウェスタン ユニバーシティ オリゴヌクレオチド官能化金属有機構造体ナノ粒子を調製するための一般的かつ直接的な方法
US20200384104A1 (en) * 2017-12-15 2020-12-10 Northwestern University Structure-Function Relationships in the Development of Immunotherapeutic Agents
US20190314291A1 (en) * 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
US20220088059A1 (en) * 2019-02-12 2022-03-24 Exicure Operating Company Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapy
WO2020219985A1 (en) * 2019-04-26 2020-10-29 Exicure, Inc. Administration of spherical nucleic acids for ophthalmological uses

Similar Documents

Publication Publication Date Title
JP2022544412A5 (cg-RX-API-DMAC7.html)
JP2025501610A5 (cg-RX-API-DMAC7.html)
JP2025500481A5 (cg-RX-API-DMAC7.html)
JP6577073B2 (ja) ベータ−ENaC−関連疾患を処置するための有機組成物
US20240309367A1 (en) Lipid nanoparticle spherical nucleic acids
CN111918968B (zh) Micro-RNA 22的抑制剂
JP7560616B2 (ja) 膜貫通型セリンプロテアーゼ6(tmprss6)発現を阻害するための組成物および方法
CN111971051A (zh) 用增加tm的核苷酸修饰的双链核酸抑制剂分子
JP2025148338A (ja) Rna治療薬及びその使用方法
EP4463553A1 (en) Advanced rna targeting (arnatar)
JP2024071571A (ja) ミトコンドリアアミドキシム還元成分1(marc1)発現を阻害するための組成物および方法
KR20240099322A (ko) 조건-활성화가능한 핵산 구축물 및 신경계 질환을 치료하기 위한 그의 용도
US20260043031A1 (en) Compositions and methods for inhibiting adenylate cyclase 9 (ac9)
TW202308660A (zh) 用於抑制α-1抗胰蛋白酶表現之組合物及方法
JP2024537098A5 (cg-RX-API-DMAC7.html)
WO2024121814A1 (en) Modified immunomodulators
WO2025162482A1 (zh) 用于预防和治疗癌症转移的aso及其用途
US20220340912A1 (en) Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
WO2025165840A1 (en) Compositions and methods of treating cardiovascular disease
US20240150768A1 (en) Methods for the treatment of nash with advanced fibrosis and/or cirrhosis
Riasi et al. Gene Silencing Method Based on DNA.
TW202345873A (zh) 調節scap活性之組合物及方法
JP2026510983A (ja) 環状アンチセンス治療薬
WO2025208204A1 (en) Compositions and methods for inhibiting expression or function of exchange protein directly activated by camp (epac)
HK40127600A (en) Compositions and methods for inhibiting adenylate cyclase 9 (ac9)